There are presently 15 research collaborations underway to enable academic researchers to discover novel therapies for the COVID-19 pandemic and those in the future using advanced artificial intelligence (AI) technology developed by Atomwise Inc. (San Francisco, CA, USA).
Atomwise has forged fifteen research collaborations with universities globally to develop broad-spectrum treatments for Covid-19, as well as other coronaviruses.
A UniSA molecular biologist is working with a world leader in artificial intelligence-based drug discovery to help find a molecule that could prevent the SARS-CoV-2 coronavirus strain causing COVID-19 from infecting human cells.
Molecule prospector Atomwise co-founded a drug research company alongside Velocity Pharmaceutical Development designed to shepherd its artificial intelligence-derived candidates through preclinical testing and into potential takeout deals with pharma industry partners. Dubbed X-37, the new firm will maintain a flexible LLC structure that will house each development program within its own virtual subcompany. This will […]
Angus Liu of FierceBiotech reports on new research on Miro1 and implications for Parkinson’s disease.